599 related articles for article (PubMed ID: 25681448)
1. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Miller DH; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Kita M; Wheeler-Kingshott CA; Tozer DJ; MacManus DG; Yousry TA; Goodsell M; Yang M; Zhang R; Viglietta V; Dawson KT;
Neurology; 2015 Mar; 84(11):1145-52. PubMed ID: 25681448
[TBL] [Abstract][Full Text] [Related]
2. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Sep; 261(9):1794-802. PubMed ID: 24989666
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
[TBL] [Abstract][Full Text] [Related]
4. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
6. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
J Neurol; 2014 Dec; 261(12):2429-37. PubMed ID: 25270680
[TBL] [Abstract][Full Text] [Related]
7. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
8. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
9. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
10. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries.
Saida T; Yamamura T; Kondo T; Yun J; Yang M; Li J; Mahadavan L; Zhu B; Sheikh SI
BMC Neurol; 2019 Jan; 19(1):5. PubMed ID: 30616596
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
Hutchinson M; Fox RJ; Miller DH; Phillips JT; Kita M; Havrdova E; O'Gorman J; Zhang R; Novas M; Viglietta V; Dawson KT
J Neurol; 2013 Sep; 260(9):2286-96. PubMed ID: 23749293
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN;
Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Bar-Or A; Gold R; Kappos L; Arnold DL; Giovannoni G; Selmaj K; O'Gorman J; Stephan M; Dawson KT
J Neurol; 2013 Sep; 260(9):2297-305. PubMed ID: 23797999
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
17. Dimethyl fumarate for multiple sclerosis.
Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
[TBL] [Abstract][Full Text] [Related]
18. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
Matolcsi J; Rózsa C
Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
[TBL] [Abstract][Full Text] [Related]
19. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
20. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
